Thus, in light of various studies, a significant link has been identified connecting NLRP3 with obesity and T2D; therefore, targeting NLRP3 could be beneficial for the treatment of the above-mentioned metabolic diseases. Here, NLRP3 is linked to obesity due to melanocortin 4 receptor deficiency.